Adam Davidson, CEO of Trident Royalties, discusses offtake milestones and catalysts to boost FY24. Watch the video here.
Gunto - you are trying really hard to luck clever.
The majority of the TFG investment was pre phase 3 results. They bought between £2 and say £1.00. The share price is now c. 6p.
The interview with Reade Griffith (I believe is Oct 2022) after trial failure. That doesn't tell you anything about how Synairgen will turn this mess around.
I don't understand the link the between one interview which means everything will come good.
Gunto - why are you pretending you are in the know.
Johnnyboy - 'the science' - I'm sure we failed our last phase 3 and the drug hasn't been used since Nov 21. 'The science' sounds like an old banger that won't start.
Oh and timeframes. RNS April 2022 (yes 2022) stated they were considering new trials. RNS September 2023 states trials would start by end of 2023.
We are currently 'on track' for an already delayed trial start date.
Nothing to worry about here.
TP - good post. Thank you.
The next update from the company has to be 'this is what is happening' and not the usual 'subject to...' waffle we have been provided with for the last two years.
On TFG, I'm not convinced they are actually overly concerned what Synairgen does or does not achieve. Consider TFG's entire portfolio, if Synairgen fails its business as usual for TFG.
Fruits - We have no idea what talks the company are involved in. Why? Because we haven't had an update since September!
To suggest I am burying my head in the sand is poor form. Please tell me what news I am ignoring?
Forgive me for not having confidence in the company, of course they have a clear plan.
I should be more trusting of the directors when considering the following:
SNG not used in trials since Nov 2021.
CEO not providing updates.
Delayed new trials from RNS in 2022.
MCAP from £230M to 10M.
Of course, the directors have got a clear plan!
Jint - I appreciate your clear intent for positive news.
Authorisation? We are at least 3-4 years away from this IF we get some luck on along the way.
New phase 2 trials discussed in 2022 haven't even started which will involve around 100 patients. Who is approving the drug at that stage? This company appears to be no rush to obtain authorisation.
Sadly, this company remains research company, no commercial activity ever in their 22+ year history.
I don't think I can make any profit from this share save for buying additional shares during the 4-5p range which will assist my recovery IF we get some good news.
If I can recover 30-40% of my 'investment' then I will be happy with the outcome and move on. I won't be getting involved in the stock market again.
Macosta? Please, its Mr Costs.
Most are happy to wait until end of H1? Seriously?
Do you really think our CEO will start trials within H1? Read the Sept RNS again, trials to start by end of H1 2024 SUBJECT TO...
Marsden has again provided a politicians update that when we arrive at end of H1, he can blame something external whilst his salary keeps on being paid.
'What's another month or two' Ask Marsden and he will tell you £25-50K in salary.
Scaermongering? The share price from c. £2 all the way down c. 4p did it for me.
So its agreed the article doesn't mention SNG001 or Synairgen directly?
More pin the tail on the donkey.
Brand - please copy and paste part(s) of the article which mentions SNG001 or Synairgen directly.
Not really a great find is it. No mention of SNG001 or Synairgen.
Our co founder is mentioned who also happens to have many interests outside of Synairgen. So What?
All this flirting could be sorted with an update from the company themselves.